{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T07:25:58Z","timestamp":1776497158295,"version":"3.51.2"},"reference-count":94,"publisher":"Bentham Science Publishers Ltd.","issue":"27","funder":[{"DOI":"10.13039\/501100003407","name":"Italian Ministry of University and Research (MIUR), PRIN 2017","doi-asserted-by":"publisher","award":["2017MT3993_007"],"award-info":[{"award-number":["2017MT3993_007"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Fyn kinase is a member of the Src non-receptor tyrosine kinase family. Fyn is\ninvolved in multiple signaling pathways extending from cell proliferation and differentiation\nto cell adhesion and cell motility, and it has been found to be overexpressed in various\ntypes of cancers. In the central nervous system, Fyn exerts several different functions\nsuch as axon\u2013glial signal transduction, oligodendrocyte maturation, and myelination, and\nit is implicated in neuroinflammatory processes. Based on these premises, Fyn emerges as\nan attractive target in cancer and neurodegenerative disease therapy, particularly Alzheimer\u2019s\ndisease (AD), based on its activation by A\u03b2 via cellular prion protein and its interaction\nwith tau protein. However, Fyn is also a challenging target since the Fyn inhibitors\ndiscovered so far, due to the relevant homology of Fyn with other kinases, suffer\nfrom off-target effects. This review covers the efforts performed in the last decade to\nidentify and optimize small molecules that effectively inhibit Fyn, both in enzymatic and\nin cell assays, including drug repositioning practices, as an opportunity for therapeutic intervention\nin neurodegeneration.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867329666211221153719","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T14:42:23Z","timestamp":1640270543000},"page":"4738-4755","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Role of Fyn Kinase Inhibitors in Switching Neuroinflammatory Pathways"],"prefix":"10.2174","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5846-3532","authenticated-orcid":true,"given":"Giambattista","family":"Marotta","sequence":"first","affiliation":[{"name":"Department of Pharmacy and Biotechnology, Alma Mater Studiorum \u2013 University of Bologna, via Belmeloro\n6, Bologna, 40126, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0710-4251","authenticated-orcid":true,"given":"Filippo","family":"Basagni","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Biotechnology, Alma Mater Studiorum \u2013 University of Bologna, via Belmeloro\n6, Bologna, 40126, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3750-2728","authenticated-orcid":true,"given":"Michela","family":"Rosini","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Biotechnology, Alma Mater Studiorum \u2013 University of Bologna, via Belmeloro\n6, Bologna, 40126, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4905-0944","authenticated-orcid":true,"given":"Anna","family":"Minarini","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Biotechnology, Alma Mater Studiorum \u2013 University of Bologna, via Belmeloro\n6, Bologna, 40126, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"7918","DOI":"10.1038\/sj.onc.1208081","volume":"23","author":"Boggon T.J.","year":"2004","unstructured":"Boggon T.J.; Eck M.J.; Structure and regulation of Src family kinases. Oncogene 2004,23(48),7918-7927","journal-title":"Oncogene"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3233\/JAD-2011-110353","volume":"27","author":"Yang K.","year":"2011","unstructured":"Yang K.; Belrose J.; Trepanier C.H.; Lei G.; Jackson M.F.; MacDonald J.F.; Fyn, a potential target for Alzheimer\u2019s disease. J Alzheimers Dis 2011,27(2),243-252","journal-title":"J Alzheimers Dis"},{"key":"ref=3","first-page":"66","volume":"1","author":"Cooke M.P.","year":"1989","unstructured":"Cooke M.P.; Perlmutter R.M.; Expression of a novel form of the fyn proto-oncogene in hematopoietic cells. New Biol 1989,1(1),66-74","journal-title":"New Biol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"4444","DOI":"10.3390\/ijms21124444","volume":"21","author":"Matrone C.","year":"2020","unstructured":"Matrone C.; Petrillo F.; Nasso R.; Ferretti G.; Fyn tyrosine kinase as harmonizing factor in neuronal functions and dysfunctions. Int J Mol Sci 2020,21(12),4444","journal-title":"Int J Mol Sci"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.2174\/092986711796150531","volume":"18","author":"Schenone S.","year":"2011","unstructured":"Schenone S.; Brullo C.; Musumeci F.; Biava M.; Falchi F.; Botta M.; Fyn kinase in brain diseases and cancer: The search for inhibitors. Curr Med Chem 2011,18(19),2921-2942","journal-title":"Curr Med Chem"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/nrc1366","volume":"4","author":"Yeatman T.J.","year":"2004","unstructured":"Yeatman T.J.; A renaissance for SRC. Nat Rev Cancer 2004,4(6),470-480","journal-title":"Nat Rev Cancer"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.3390\/cancers12061448","volume":"12","author":"Martellucci S.","year":"2020","unstructured":"Martellucci S.; Clementi L.; Sabetta S.; Mattei V.; Botta L.; Angelucci A.; Src family kinases as therapeutic targets in advanced solid tumors: what we have learned so far. Cancers (Basel) 2020,12(6),1448","journal-title":"Cancers (Basel)"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/alzrt238","volume":"6","author":"Nygaard H.B.","year":"2014","unstructured":"Nygaard H.B.; van Dyck C.H.; Strittmatter S.M.; Fyn kinase inhibition as a novel therapy for Alzheimer\u2019s disease. Alzheimers Res Ther 2014,6(1),8","journal-title":"Alzheimers Res Ther"},{"key":"ref=9","first-page":"3343","volume":"8","author":"Yagi T.","year":"1993","unstructured":"Yagi T.; Shigetani Y.; Okado N.; Tokunaga T.; Ikawa Y.; Aizawa S.; Regional localization of Fyn in adult brain; studies with mice in which fyn gene was replaced by lacZ. Oncogene 1993,8(12),3343-3351","journal-title":"Oncogene"},{"key":"ref=10","first-page":"2433","volume":"9","author":"Yagi T.","year":"1994","unstructured":"Yagi T.; Shigetani Y.; Furuta Y.; Nada S.; Okado N.; Ikawa Y.; Aizawa S.; Fyn expression during early neurogenesis in mouse embryos. Oncogene 1994,9(9),2433-2440","journal-title":"Oncogene"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/0169-328X(92)90239-8","volume":"16","author":"Umemori H.","year":"1992","unstructured":"Umemori H.; Wanaka A.; Kato H.; Takeuchi M.; Tohyama M.; Yamamoto T.; Specific expressions of Fyn and Lyn, lymphocyte antigen receptor-associated tyrosine kinases, in the central nervous system. Brain Res Mol Brain Res 1992,16(3-4),303-310","journal-title":"Brain Res Mol Brain Res"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1523\/JNEUROSCI.21-06-02039.2001","volume":"21","author":"Sperber B.R.","year":"2001","unstructured":"Sperber B.R.; Boyle-Walsh E.A.; Engleka M.J.; Gadue P.; Peterson A.C.; Stein P.L.; Scherer S.S.; McMorris F.A.; A unique role for Fyn in CNS myelination. J Neurosci 2001,21(6),2039-2047","journal-title":"J Neurosci"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1093\/brain\/awn334","volume":"132","author":"Baer A.S.","year":"2009","unstructured":"Baer A.S.; Syed Y.A.; Kang S.U.; Mitteregger D.; Vig R.; Ffrench-Constant C.; Franklin R.J.; Altmann F.; Lubec G.; Kotter M.R.; Myelin-mediated inhibition of oligodendrocyte precursor differentiation can be overcome by pharmacological modulation of Fyn-RhoA and protein kinase C signalling. Brain 2009,132(Pt 2),465-481","journal-title":"Brain"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.tins.2011.09.005","volume":"34","author":"Ohnishi H.","year":"2011","unstructured":"Ohnishi H.; Murata Y.; Okazawa H.; Matozaki T.; Src family kinases: modulators of neurotransmitter receptor function and behavior. Trends Neurosci 2011,34(12),629-637","journal-title":"Trends Neurosci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1742-4658.2011.08391.x","volume":"279","author":"Trepanier C.H.","year":"2012","unstructured":"Trepanier C.H.; Jackson M.F.; MacDonald J.F.; Regulation of NMDA receptors by the tyrosine kinase Fyn. FEBS J 2012,279(1),12-19","journal-title":"FEBS J"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1083\/jcb.145.6.1209","volume":"145","author":"Osterhout D.J.","year":"1999","unstructured":"Osterhout D.J.; Wolven A.; Wolf R.M.; Resh M.D.; Chao M.V.; Morphological differentiation of oligodendrocytes requires activation of Fyn tyrosine kinase. J Cell Biol 1999,145(6),1209-1218","journal-title":"J Cell Biol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/00001756-199304000-00024","volume":"4","author":"Shirazi S.K.","year":"1993","unstructured":"Shirazi S.K.; Wood J.G.; The protein tyrosine kinase, fyn, in Alzheimer\u2019s disease pathology. Neuroreport 1993,4(4),435-437","journal-title":"Neuroreport"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.cell.2010.06.036","volume":"142","author":"Ittner L.M.","year":"2010","unstructured":"Ittner L.M.; Ke Y.D.; Delerue F.; Bi M.; Gladbach A.; van Eersel J.; W\u00f6lfing H.; Chieng B.C.; Christie M.J.; Napier I.A.; Eckert A.; Staufenbiel M.; Hardeman E.; G\u00f6tz J.; Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer\u2019s disease mouse models. Cell 2010,142(3),387-397","journal-title":"Cell"},{"key":"ref=19","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108045","volume":"32","author":"Briner A.","year":"2020","unstructured":"Briner A.; G\u00f6tz J.; Polanco J.C.; Fyn kinase controls tau aggregation in vivo. Cell Rep 2020,32(7)","journal-title":"Cell Rep"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1523\/JNEUROSCI.23-07-02665.2003","volume":"23","author":"Bamberger M.E.","year":"2003","unstructured":"Bamberger M.E.; Harris M.E.; McDonald D.R.; Husemann J.; Landreth G.E.; A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J Neurosci 2003,23(7),2665-2674","journal-title":"J Neurosci"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/nchem.247","volume":"1","author":"Bernstein S.L.","year":"2009","unstructured":"Bernstein S.L.; Dupuis N.F.; Lazo N.D.; Wyttenbach T.; Condron M.M.; Bitan G.; Teplow D.B.; Shea J.E.; Ruotolo B.T.; Robinson C.V.; Bowers M.T.; Amyloid-\u03b2 protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer\u2019s disease. Nat Chem 2009,1(4),326-331","journal-title":"Nat Chem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/nature07761","volume":"457","author":"Laur\u00e9n J.","year":"2009","unstructured":"Laur\u00e9n J.; Gimbel D.A.; Nygaard H.B.; Gilbert J.W.; Strittmatter S.M.; Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009,457(7233),1128-1132","journal-title":"Nature"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","volume":"95","author":"Lambert M.P.","year":"1998","unstructured":"Lambert M.P.; Barlow A.K.; Chromy B.A.; Edwards C.; Freed R.; Liosatos M.; Morgan T.E.; Rozovsky I.; Trommer B.; Viola K.L.; Wals P.; Zhang C.; Finch C.E.; Krafft G.A.; Klein W.L.; Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998,95(11),6448-6453","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1523\/JNEUROSCI.0277-04.2004","volume":"24","author":"Chin J.","year":"2004","unstructured":"Chin J.; Palop J.J.; Yu G.Q.; Kojima N.; Masliah E.; Mucke L.; Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J Neurosci 2004,24(19),4692-4697","journal-title":"J Neurosci"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.3390\/cells9081807","volume":"9","author":"Iannuzzi F.","year":"2020","unstructured":"Iannuzzi F.; Sirabella R.; Canu N.; Maier T.J.; Annunziato L.; Matrone C.; Fyn tyrosine kinase elicits amyloid precursor protein tyr682 phosphorylation in neurons from alzheimer\u2019s disease patients. Cells 2020,9(8),1807","journal-title":"Cells"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.cell.2010.07.032","volume":"142","author":"Haass C.","year":"2010","unstructured":"Haass C.; Mandelkow E.; Fyn-tau-amyloid: a toxic triad. Cell 2010,142(3),356-358","journal-title":"Cell"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/nn.3178","volume":"15","author":"Um J.W.","year":"2012","unstructured":"Um J.W.; Nygaard H.B.; Heiss J.K.; Kostylev M.A.; Stagi M.; Vortmeyer A.; Wisniewski T.; Gunther E.C.; Strittmatter S.M.; Alzheimer amyloid-\u03b2 oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci 2012,15(9),1227-1235","journal-title":"Nat Neurosci"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1007\/s12035-020-02201-z","volume":"58","author":"Angelopoulou E.","year":"2021","unstructured":"Angelopoulou E.; Paudel Y.N.; Julian T.; Shaikh M.F.; Piperi C.; Pivotal role of fyn kinase in Parkinson\u2019s disease and levodopa-induced dyskinesia: a novel therapeutic target? Mol Neurobiol 2021,58(4),1372-1391","journal-title":"Mol Neurobiol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.nbd.2017.11.008","volume":"110","author":"Sharma S.","year":"2018","unstructured":"Sharma S.; Carlson S.; Puttachary S.; Sarkar S.; Showman L.; Putra M.; Kanthasamy A.G.; Thippeswamy T.; Role of the Fyn-PKC\u03b4 signaling in SE-induced neuroinflammation and epileptogenesis in experimental models of temporal lobe epilepsy. Neurobiol Dis 2018,110,102-121","journal-title":"Neurobiol Dis"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"10058","DOI":"10.1523\/JNEUROSCI.0302-15.2015","volume":"35","author":"Panicker N.","year":"2015","unstructured":"Panicker N.; Saminathan H.; Jin H.; Neal M.; Harischandra D.S.; Gordon R.; Kanthasamy K.; Lawana V.; Sarkar S.; Luo J.; Anantharam V.; Kanthasamy A.G.; Kanthasamy A.; Fyn kinase regulates microglial neuroinflammatory responses in cell culture and animal models of Parkinson\u2019s disease. J Neurosci 2015,35(27),10058-10077","journal-title":"J Neurosci"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41467-017-00294-0","volume":"8","author":"Mkaddem S.B.","year":"2017","unstructured":"Mkaddem S.B.; Murua A.; Flament H.; Titeca-Beauport D.; Bounaix C.; Danelli L.; Launay P.; Benhamou M.; Blank U.; Daugas E.; Charles N.; Monteiro R.C.; Lyn and Fyn function as molecular switches that control immunoreceptors to direct homeostasis or inflammation. Nat Commun 2017,8(1),246","journal-title":"Nat Commun"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/jnc.13429","volume":"136","author":"Lee C.","year":"2016","unstructured":"Lee C.; Low C.Y.; Francis P.T.; Attems J.; Wong P.T.; Lai M.K.; Tan M.G.; An isoform-specific role of FynT tyrosine kinase in Alzheimer\u2019s disease. J Neurochem 2016,136(3),637-650","journal-title":"J Neurochem"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"43651","DOI":"10.1038\/srep43651","volume":"7","author":"Lee C.","year":"2017","unstructured":"Lee C.; Low C.Y.; Wong S.Y.; Lai M.K.; Tan M.G.; Selective induction of alternatively spliced FynT isoform by TNF facilitates persistent inflammatory responses in astrocytes. Sci Rep 2017,7,43651","journal-title":"Sci Rep"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s40478-020-00976-9","volume":"8","author":"Tang S.J.","year":"2020","unstructured":"Tang S.J.; Fesharaki-Zadeh A.; Takahashi H.; Nies S.H.; Smith L.M.; Luo A.; Chyung A.; Chiasseu M.; Strittmatter S.M.; Fyn kinase inhibition reduces protein aggregation, increases synapse density and improves memory in transgenic and traumatic Tauopathy. Acta Neuropathol Commun 2020,8(1),96","journal-title":"Acta Neuropathol Commun"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/ana.24394","volume":"77","author":"Kaufman A.C.","year":"2015","unstructured":"Kaufman A.C.; Salazar S.V.; Haas L.T.; Yang J.; Kostylev M.A.; Jeng A.T.; Robinson S.A.; Gunther E.C.; van Dyck C.H.; Nygaard H.B.; Strittmatter S.M.; Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. Ann Neurol 2015,77(6),953-971","journal-title":"Ann Neurol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1021\/acschembio.9b00214","volume":"14","author":"Chakraborty S.","year":"2019","unstructured":"Chakraborty S.; Inukai T.; Fang L.; Golkowski M.; Maly D.J.; Targeting dynamic atp-binding site features allows discrimination between highly homologous protein kinases. ACS Chem Biol 2019,14(6),1249-1259","journal-title":"ACS Chem Biol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0968-0004(98)01202-X","volume":"23","author":"Williams J.C.","year":"1998","unstructured":"Williams J.C.; Wierenga R.K.; Saraste M.; Insights into Src kinase functions: structural comparisons. Trends Biochem Sci 1998,23(5),179-184","journal-title":"Trends Biochem Sci"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.bbrc.2006.05.212","volume":"346","author":"Kinoshita T.","year":"2006","unstructured":"Kinoshita T.; Matsubara M.; Ishiguro H.; Okita K.; Tada T.; Structure of human Fyn kinase domain complexed with staurosporine. Biochem Biophys Res Commun 2006,346(3),840-844","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1039\/C9MD00519F","volume":"11","author":"Rachman M.","year":"2020","unstructured":"Rachman M.; Bajusz D.; Het\u00e9nyi A.; Scarpino A.; Mer\u0151 B.; Egyed A.; Buday L.; Barril X.; Keser\u0171 G.M.; Discovery of a novel kinase hinge binder fragment by dynamic undocking. RSC Med Chem 2020,11(5),552-558","journal-title":"RSC Med Chem"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.biopsych.2017.06.004","volume":"83","author":"Nygaard H.B.","year":"2018","unstructured":"Nygaard H.B.; Targeting fyn kinase in Alzheimer\u2019s disease. Biol Psychiatry 2018,83(4),369-376","journal-title":"Biol Psychiatry"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"6465","DOI":"10.1021\/jm060434q","volume":"49","author":"Hennequin L.F.","year":"2006","unstructured":"Hennequin L.F.; Allen J.; Breed J.; Curwen J.; Fennell M.; Green T.P.; Lambert-van der Brempt C.; Morgentin R.; Norman R.A.; Olivier A.; Otterbein L.; Pl\u00e9 P.A.; Warin N.; Costello G.N.; -(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src\/Abl kinase inhibitor. J Med Chem 2006,49(22),6465-6488","journal-title":"J Med Chem"},{"key":"ref=42","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12044","volume":"6","author":"Fagiani F.","year":"2020","unstructured":"Fagiani F.; Lanni C.; Racchi M.; Govoni S.; Targeting dementias through cancer kinases inhibition. Alzheimers Dement (N Y) 2020,6(1)","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13195-015-0119-0","volume":"7","author":"Nygaard H.B.","year":"2015","unstructured":"Nygaard H.B.; Wagner A.F.; Bowen G.S.; Good S.P.; MacAvoy M.G.; Strittmatter K.A.; Kaufman A.C.; Rosenberg B.J.; Sekine-Konno T.; Varma P.; Chen K.; Koleske A.J.; Reiman E.M.; Strittmatter S.M.; van Dyck C.H.; A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer\u2019s disease. Alzheimers Res Ther 2015,7(1),35","journal-title":"Alzheimers Res Ther"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1001\/jamaneurol.2019.2050","volume":"76","author":"van Dyck C.H.","year":"2019","unstructured":"van Dyck C.H.; Nygaard H.B.; Chen K.; Donohue M.C.; Raman R.; Rissman R.A.; Brewer J.B.; Koeppe R.A.; Chow T.W.; Rafii M.S.; Gessert D.; Choi J.; Turner R.S.; Kaye J.A.; Gale S.A.; Reiman E.M.; Aisen P.S.; Strittmatter S.M.; Effect of AZD0530 on cerebral metabolic decline in Alzheimer disease: a randomized clinical trial. JAMA Neurol 2019,76(10),1219-1229","journal-title":"JAMA Neurol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1111\/j.1939-1676.2008.0190.x","volume":"22","author":"Hahn K.A.","year":"2008","unstructured":"Hahn K.A.; Ogilvie G.; Rusk T.; Devauchelle P.; Leblanc A.; Legendre A.; Powers B.; Leventhal P.S.; Kinet J.P.; Palmerini F.; Dubreuil P.; Moussy A.; Hermine O.; Hermine O.; Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 2008,22(6),1301-1309","journal-title":"J Vet Intern Med"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1586\/14737175.2015.1045419","volume":"15","author":"Folch J.","year":"2015","unstructured":"Folch J.; Petrov D.; Ettcheto M.; Pedr\u00f3s I.; Abad S.; Beas-Zarate C.; Lazarowski A.; Marin M.; Olloquequi J.; Auladell C.; Camins A.; Masitinib for the treatment of mild to moderate Alzheimer\u2019s disease. Expert Rev Neurother 2015,15(6),587-596","journal-title":"Expert Rev Neurother"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/alzrt75","volume":"3","author":"Piette F.","year":"2011","unstructured":"Piette F.; Belmin J.; Vincent H.; Schmidt N.; Pariel S.; Verny M.; Marquis C.; Mely J.; Hugonot-Diener L.; Kinet J.P.; Dubreuil P.; Moussy A.; Hermine O.; Masitinib as an adjunct therapy for mild-to-moderate Alzheimer\u2019s disease: a randomised, placebo-controlled phase 2 trial. Alzheimers Res Ther 2011,3(2),16","journal-title":"Alzheimers Res Ther"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/21678421.2019.1632346","volume":"21","author":"Mora J.S.","year":"2020","unstructured":"Mora J.S.; Genge A.; Chio A.; Estol C.J.; Chaverri D.; Hern\u00e1ndez M.; Mar\u00edn S.; Mascias J.; Rodriguez G.E.; Povedano M.; Paipa A.; Dominguez R.; Gamez J.; Salvado M.; Lunetta C.; Ballario C.; Riva N.; Mandrioli J.; Moussy A.; Kinet J.P.; Auclair C.; Dubreuil P.; Arnold V.; Mansfield C.D.; Hermine O.; Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener 2020,21(1-2),5-14","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","volume":"66","author":"Tokarski J.S.","year":"2006","unstructured":"Tokarski J.S.; Newitt J.A.; Chang C.Y.; Cheng J.D.; Wittekind M.; Kiefer S.E.; Kish K.; Lee F.Y.; Borzillerri R.; Lombardo L.J.; Xie D.; Zhang Y.; Klei H.E.; The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006,66(11),5790-5797","journal-title":"Cancer Res"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"6819","DOI":"10.1021\/jm060727j","volume":"49","author":"Das J.","year":"2006","unstructured":"Das J.; Chen P.; Norris D.; Padmanabha R.; Lin J.; Moquin R.V.; Shen Z.; Cook L.S.; Doweyko A.M.; Pitt S.; Pang S.; Shen D.R.; Fang Q.; de Fex H.F.; McIntyre K.W.; Shuster D.J.; Gillooly K.M.; Behnia K.; Schieven G.L.; Wityak J.; Barrish J.C.; 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem 2006,49(23),6819-6832","journal-title":"J Med Chem"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1742-2094-9-117","volume":"9","author":"Dhawan G.","year":"2012","unstructured":"Dhawan G.; Combs C.K.; Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer\u2019s disease. J Neuroinflammation 2012,9,117","journal-title":"J Neuroinflammation"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41593-019-0372-9","volume":"22","author":"Zhang P.","year":"2019","unstructured":"Zhang P.; Kishimoto Y.; Grammatikakis I.; Gottimukkala K.; Cutler R.G.; Zhang S.; Abdelmohsen K.; Bohr V.A.; Misra Sen J.; Gorospe M.; Mattson M.P.; Senolytic therapy alleviates A\u03b2-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer\u2019s disease model. Nat Neurosci 2019,22(5),719-728","journal-title":"Nat Neurosci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1074\/jbc.271.2.695","volume":"271","author":"Hanke J.H.","year":"1996","unstructured":"Hanke J.H.; Gardner J.P.; Dow R.L.; Changelian P.S.; Brissette W.H.; Weringer E.J.; Pollok B.A.; Connelly P.A.; Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem 1996,271(2),695-701","journal-title":"J Biol Chem"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00044-020-02656-8","volume":"30","author":"Abdellatif K.R.A.","year":"2021","unstructured":"Abdellatif K.R.A.; Bakr R.B.; Pyridine and fused pyrimidine derivatives as promising protein kinase inhibitors for cancer treatment. Med Chem Res 2021,30,31-49","journal-title":"Med Chem Res"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.3892\/ol.2017.5564","volume":"13","author":"Shim H.J.","year":"2017","unstructured":"Shim H.J.; Kim H.I.; Lee S.T.; The associated pyrazolopyrimidines PP1 and PP2 inhibit protein tyrosine kinase 6 activity and suppress breast cancer cell proliferation. Oncol Lett 2017,13(3),1463-1469","journal-title":"Oncol Lett"},{"key":"ref=56","author":"Lau W.C.","year":"2017","unstructured":"Lau W.C.; Methods, compositions and uses of novel Fyn kinase inhibitors, 2017"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"4590","DOI":"10.1021\/acs.jmedchem.5b00140","volume":"58","author":"Tintori C.","year":"2015","unstructured":"Tintori C.; La Sala G.; Vignaroli G.; Botta L.; Fallacara A.L.; Falchi F.; Radi M.; Zamperini C.; Dreassi E.; Dello Iacono L.; Orioli D.; Biamonti G.; Garbelli M.; Lossani A.; Gasparrini F.; Tuccinardi T.; Laurenzana I.; Angelucci A.; Maga G.; Schenone S.; Brullo C.; Musumeci F.; Desogus A.; Crespan E.; Botta M.; Studies on the atp binding site of fyn kinase for the identification of new inhibitors and their evaluation as potential agents against tauopathies and tumors. J Med Chem 2015,58(11),4590-4609","journal-title":"J Med Chem"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.2174\/0929867324666170303162100","volume":"24","author":"Musumeci F.","year":"2017","unstructured":"Musumeci F.; Sanna M.; Grossi G.; Brullo C.; Fallacara A.L.; Schenone S.; Pyrrolo[2,3-d]pyrimidines as kinase inhibitors. Curr Med Chem 2017,24(19),2059-2085","journal-title":"Curr Med Chem"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.3109\/14756366.2012.715288","volume":"28","author":"Dincer S.","year":"2013","unstructured":"Dincer S.; Cetin K.T.; Onay-Besikci A.; \u00d6lgen S.; Synthesis, biological evaluation and docking studies of new pyrrolo[2,3-d] pyrimidine derivatives as Src family-selective tyrosine kinase inhibitors. J Enzyme Inhib Med Chem 2013,28(5),1080-1087","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"98","DOI":"10.2174\/138955712798995039","volume":"12","author":"Prakash C.R.","year":"2012","unstructured":"Prakash C.R.; Raja S.; Indolinones as promising scaffold as kinase inhibitors: a review. Mini Rev Med Chem 2012,12(2),98-119","journal-title":"Mini Rev Med Chem"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.bmcl.2003.09.069","volume":"14","author":"Guan H.","year":"2004","unstructured":"Guan H.; Laird A.D.; Blake R.A.; Tang C.; Liang C.; Design and synthesis of aminopropyl tetrahydroindole-based indolin-2-ones as selective and potent inhibitors of Src and Yes tyrosine kinase. Bioorg Med Chem Lett 2004,14(1),187-190","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2174\/157018013804142456","volume":"10","author":"Kurt K.Z.","year":"2013","unstructured":"Kurt K.Z.; Aydin D.; Isgor Y.G.; Isgor B.S.; Olgen S.; Synthesis and biological study of novel indole-3-imine-2-on derivatives as src kinase and glutathione s-transferase inhibitors. Lett Drug Des Discov 2013,10,19-26","journal-title":"Lett Drug Des Discov"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1080\/14756360310001612211","volume":"18","author":"Olgen S.","year":"2003","unstructured":"Olgen S.; Akaho E.; Nebioglu D.; Evaluation of indole esters as inhibitors of p60(c-Src) receptor tyrosine kinase and investigation of the inhibition using receptor docking studies. J Enzyme Inhib Med Chem 2003,18(6),485-490","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/ardp.200800216","volume":"342","author":"Kili\u00e7 Z.","year":"2009","unstructured":"Kili\u00e7 Z.; Isg\u00f6r Y.G.; Olgen S.; Synthesis and pp60c-Src tyrosine kinase inhibitory activities of novel indole-3-imine and amine derivatives substituted at N1 and C5. Arch Pharm (Weinheim) 2009,342(6),333-343","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2174\/15701808113109070023","volume":"10","author":"Kilic-Kurt Z.","year":"2013","unstructured":"Kilic-Kurt Z.; Onay-Besikci A.; \u00d6lgen S.; Synthesis, biological and computational evaluation of novel oxindole derivatives as inhibitors of src family kinases. Lett Drug Des Discov 2013,10,713-718","journal-title":"Lett Drug Des Discov"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"844","DOI":"10.2174\/1573406417666210601144510","volume":"17","author":"Schade N.","year":"2021","unstructured":"Schade N.; Koch P.; Ansideri F.; Krystof V.; Holzer M.; Hilgeroth A.; Evaluation of novel substituted furopyridines as inhibitors of protein kinases related to tau pathology in Alzheimer\u00b4s disease. Med Chem 2021,17(8),844-855","journal-title":"Med Chem"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.3390\/cancers12082327","volume":"12","author":"Jha V.","year":"2020","unstructured":"Jha V.; Macchia M.; Tuccinardi T.; Poli G.; Three-dimensional interactions analysis of the anticancer target c-src kinase with its inhibitors. Cancers (Basel) 2020,12(8),2327","journal-title":"Cancers (Basel)"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1002\/cmdc.201500428","volume":"10","author":"Francini C.M.","year":"2015","unstructured":"Francini C.M.; Fallacara A.L.; Artusi R.; Mennuni L.; Calgani A.; Angelucci A.; Schenone S.; Botta M.; Identification of aminoimidazole and aminothiazole derivatives as SRC family kinase inhibitors. ChemMedChem 2015,10(12),2027-2041","journal-title":"ChemMedChem"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.3390\/molecules23092369","volume":"23","author":"Francini C.M.","year":"2018","unstructured":"Francini C.M.; Musumeci F.; Fallacara A.L.; Botta L.; Molinari A.; Artusi R.; Mennuni L.; Angelucci A.; Schenone S.; Optimization of aminoimidazole derivatives as Src family kinase inhibitors. Molecules 2018,23(9),2369","journal-title":"Molecules"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1007\/s12272-015-0611-x","volume":"38","author":"Lee C.G.","year":"2015","unstructured":"Lee C.G.; Koo J.H.; Kim S.G.; Phytochemical regulation of Fyn and AMPK signaling circuitry. Arch Pharm Res 2015,38(12),2093-2105","journal-title":"Arch Pharm Res"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3389\/fphar.2020.00153","volume":"11","author":"Luo C.","year":"2020","unstructured":"Luo C.; Zou L.; Sun H.; Peng J.; Gao C.; Bao L.; Ji R.; Jin Y.; Sun S.; A review of the anti-inflammatory effects of rosmarinic acid on inflammatory diseases. Front Pharmacol 2020,11,153","journal-title":"Front Pharmacol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/bcpt.12335","volume":"116","author":"Rocha J.","year":"2015","unstructured":"Rocha J.; Eduardo-Figueira M.; Barateiro A.; Fernandes A.; Brites D.; Bronze R.; Duarte C.M.; Serra A.T.; Pinto R.; Freitas M.; Fernandes E.; Silva-Lima B.; Mota-Filipe H.; Sepodes B.; Anti-inflammatory effect of rosmarinic acid and an extract of Rosmarinus officinalis in rat models of local and systemic inflammation. Basic Clin Pharmacol Toxicol 2015,116(5),398-413","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1021\/jm0607202","volume":"50","author":"Jeli\u0107 D.","year":"2007","unstructured":"Jeli\u0107 D.; Mildner B.; Kostrun S.; Nuji\u0107 K.; Verbanac D.; Culi\u0107 O.; Antolovi\u0107 R.; Brandt W.; Homology modeling of human Fyn kinase structure: discovery of rosmarinic acid as a new Fyn kinase inhibitor and in silico study of its possible binding modes. J Med Chem 2007,50(6),1090-1100","journal-title":"J Med Chem"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.freeradbiomed.2018.03.028","volume":"120","author":"Rong H.","year":"2018","unstructured":"Rong H.; Liang Y.; Niu Y.; Rosmarinic acid attenuates \u03b2-amyloid-induced oxidative stress via Akt\/GSK-3\u03b2\/Fyn-mediated Nrf2 activation in PC12 cells. Free Radic Biol Med 2018,120,114-123","journal-title":"Free Radic Biol Med"},{"key":"ref=75","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108878","volume":"115","author":"Han Y.","year":"2019","unstructured":"Han Y.; Ma L.; Zhao L.; Feng W.; Zheng X.; Rosmarinic inhibits cell proliferation, invasion and migration via up-regulating miR-506 and suppressing MMP2\/16 expression in pancreatic cancer. Biomed Pharmacother 2019,115","journal-title":"Biomed Pharmacother"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"867","DOI":"10.3389\/fphar.2018.00867","volume":"9","author":"Herman F.","year":"2018","unstructured":"Herman F.; Westfall S.; Brathwaite J.; Pasinetti G.M.; Suppression of presymptomatic oxidative stress and inflammation in neurodegeneration by grape-derived polyphenols. Front Pharmacol 2018,9,867","journal-title":"Front Pharmacol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.3390\/ijms21072564","volume":"21","author":"Di Meo F.","year":"2020","unstructured":"Di Meo F.; Valentino A.; Petillo O.; Peluso G.; Filosa S.; Crispi S.; Bioactive polyphenols and neuromodulation: molecular mechanisms in neurodegeneration. Int J Mol Sci 2020,21(7),2564","journal-title":"Int J Mol Sci"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/med.21440","volume":"38","author":"de Matos A.M.","year":"2018","unstructured":"de Matos A.M.; de Macedo M.P.; Rauter A.P.; Bridging type 2 diabetes and Alzheimer\u2019s disease: assembling the puzzle pieces in the quest for the molecules with therapeutic and preventive potential. Med Res Rev 2018,38(1),261-324","journal-title":"Med Res Rev"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"11663","DOI":"10.1021\/acs.jmedchem.0c00841","volume":"63","author":"de Matos A.M.","year":"2020","unstructured":"de Matos A.M.; Bl\u00e1zquez-S\u00e1nchez M.T.; Bento-Oliveira A.; de Almeida R.F.M.; Nunes R.; Lopes P.E.M.; Machuqueiro M.; Crist\u00f3v\u00e3o J.S.; Gomes C.M.; Souza C.S.; El Idrissi I.G.; Colabufo N.A.; Diniz A.; Marcelo F.; Oliveira M.C.; L\u00f3pez \u00d3.; Fernandez-Bola\u00f1os J.G.; D\u00e4twyler P.; Ernst B.; Ning K.; Garwood C.; Chen B.; Rauter A.P.; Glucosylpolyphenols as inhibitors of a\u03b2-induced fyn kinase activation and tau phosphorylation: synthesis, membrane permeability, and exploratory target assessment within the scope of type 2 diabetes and Alzheimer\u2019s disease. J Med Chem 2020,63(20),11663-11690","journal-title":"J Med Chem"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"9463","DOI":"10.1021\/jm501069h","volume":"57","author":"Jesus A.R.","year":"2014","unstructured":"Jesus A.R.; Dias C.; Matos A.M.; de Almeida R.F.; Viana A.S.; Marcelo F.; Ribeiro R.T.; Macedo M.P.; Airoldi C.; Nicotra F.; Martins A.; Cabrita E.J.; Jim\u00e9nez-Barbero J.; Rauter A.P.; Exploiting the therapeutic potential of 8-\u03b2-d-glucopyranosylgenistein: synthesis, antidiabetic activity, and molecular interaction with islet amyloid polypeptide and amyloid \u03b2-peptide (1-42). J Med Chem 2014,57(22),9463-9472","journal-title":"J Med Chem"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.bmcl.2010.11.031","volume":"21","author":"Rawat P.","year":"2011","unstructured":"Rawat P.; Kumar M.; Rahuja N.; Lal Srivastava D.S.; Srivastava A.K.; Maurya R.; Synthesis and antihyperglycemic activity of phenolic C-glycosides. Bioorg Med Chem Lett 2011,21(1),228-233","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=82","first-page":"596","volume":"2007","author":"He L.","year":"2007","unstructured":"He L.; Zhang Y.Z.; Tanoh M.; Chen G-R.; Praly J-P.; Chrysina D.E.; Tiraidis C.; Kosmopoulou M.; Leonidas D.D.; Oikonomakos G.N.; In the search of glycogen phosphorylase inhibitors: synthesis of c\u2010 d \u2010glycopyranosyl-benzo(hydro)quinones \u2013 inhibition of and binding to glycogen phosphorylase in the crystal. Eur J Med Chem 2007,2007(4),596-606","journal-title":"Eur J Med Chem"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.freeradbiomed.2012.06.039","volume":"53","author":"Kim A.Y.","year":"2012","unstructured":"Kim A.Y.; Lee C.G.; Lee D.Y.; Li H.; Jeon R.; Ryu J.H.; Kim S.G.; Enhanced antioxidant effect of prenylated polyphenols as Fyn inhibitor. Free Radic Biol Med 2012,53(5),1198-1208","journal-title":"Free Radic Biol Med"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/j.phytochem.2009.08.023","volume":"70","author":"Yazaki K.","year":"2009","unstructured":"Yazaki K.; Sasaki K.; Tsurumaru Y.; Prenylation of aromatic compounds, a key diversification of plant secondary metabolites. Phytochemistry 2009,70(15-16),1739-1745","journal-title":"Phytochemistry"},{"key":"ref=85","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.599059","volume":"7","author":"Arthur G.","year":"2020","unstructured":"Arthur G.; Oliver W.; Klaus B.; Thomas S.; G\u00f6khan I.; Sharon B.; Isabelle T.; Pierre D.; Thierry L.; Hierarchical graph representation of pharmacophore models. Front Mol Biosci 2020,7","journal-title":"Front Mol Biosci"},{"key":"ref=86","doi-asserted-by":"publisher","DOI":"10.1002\/minf.202000059","volume":"39","author":"Seidel T.","year":"2020","unstructured":"Seidel T.; Wieder O.; Garon A.; Langer T.; Applications of the pharmacophore concept in natural product inspired drug design. Mol Inform 2020,39(11)","journal-title":"Mol Inform"},{"key":"ref=87","first-page":"81","volume":"7","author":"Qing X.","year":"2014","unstructured":"Qing X.; Lee X.Y.; De Raeymaecker J.; Tame J.; Zhang K.; De Maeyer M.; Voet A.; Pharmacophore modeling: Advances, limitations, and current utility in drug discovery. J Receptor Ligand Channel Res 2014,7,81-92","journal-title":"J Receptor Ligand Channel Res"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1021\/ci600253e","volume":"47","author":"Baroni M.","year":"2007","unstructured":"Baroni M.; Cruciani G.; Sciabola S.; Perruccio F.; Mason J.S.; A common reference framework for analyzing\/comparing proteins and ligands. Fingerprints for Ligands and Proteins (FLAP): theory and application. J Chem Inf Model 2007,47(2),279-294","journal-title":"J Chem Inf Model"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1021\/acs.jmedchem.6b00078","volume":"59","author":"Ehrt C.","year":"2016","unstructured":"Ehrt C.; Brinkjost T.; Koch O.; Impact of binding site comparisons on medicinal chemistry and rational molecular design. J Med Chem 2016,59(9),4121-4151","journal-title":"J Med Chem"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1021\/ci4002553","volume":"53","author":"Poli G.","year":"2013","unstructured":"Poli G.; Tuccinardi T.; Rizzolio F.; Caligiuri I.; Botta L.; Granchi C.; Ortore G.; Minutolo F.; Schenone S.; Martinelli A.; Identification of new Fyn kinase inhibitors using a FLAP-based approach. J Chem Inf Model 2013,53(10),2538-2547","journal-title":"J Chem Inf Model"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.suronc.2020.02.002","volume":"33","author":"Xue F.","year":"2020","unstructured":"Xue F.; Jia Y.; Zhao J.; Overexpression of FYN suppresses the epithelial-to-mesenchymal transition through down-regulating PI3K\/AKT pathway in lung adenocarcinoma. Surg Oncol 2020,33,108-117","journal-title":"Surg Oncol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.3892\/or.2016.4894","volume":"36","author":"Xie Y.G.","year":"2016","unstructured":"Xie Y.G.; Yu Y.; Hou L.K.; Wang X.; Zhang B.; Cao X.C.; FYN promotes breast cancer progression through epithelial-mesenchymal transition. Oncol Rep 2016,36(2),1000-1006","journal-title":"Oncol Rep"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1080\/14756366.2018.1469017","volume":"33","author":"Poli G.","year":"2018","unstructured":"Poli G.; Lapillo M.; Granchi C.; Caciolla J.; Mouawad N.; Caligiuri I.; Rizzolio F.; Langer T.; Minutolo F.; Tuccinardi T.; Binding investigation and preliminary optimisation of the 3-amino-1,2,4-triazin-5(2H)-one core for the development of new Fyn inhibitors. J Enzyme Inhib Med Chem 2018,33(1),956-961","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"9","DOI":"10.7554\/eLife.50571","volume":"9","author":"Mukherjee A.","year":"2020","unstructured":"Mukherjee A.; Singh R.; Udayan S.; Biswas S.; Reddy P.P.; Manmadhan S.; George G.; Kumar S.; Das R.; Rao B.M.; Gulyani A.; A Fyn biosensor reveals pulsatile, spatially localized kinase activity and signaling crosstalk in live mammalian cells. eLife 2020,9,9","journal-title":"eLife"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867329666211221153719","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/199220\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867329666211221153719","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T16:31:26Z","timestamp":1691598686000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/199220\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":94,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867329666211221153719","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-07-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}